key: cord-0708759-1rls85k7
authors: Belov, Artur; Huang, Yin; Villa, Carlos H.; Whitaker, Barbee I.; Forshee, Richard; Anderson, Steven A.; Eder, Anne; Verdun, Nicole; Joyner, Michael J.; Wright, Scott R.; Carter, Rickey E.; Hung, Deborah T.; Homer, Mary; Hoffman, Corey; Lauer, Michael; Marks, Peter
title: Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
date: 2022-03-24
journal: Am J Hematol
DOI: 10.1002/ajh.26531
sha: 3eaa4ad5da6eccb8c51452f1f41912794859d484
doc_id: 708759
cord_uid: 1rls85k7

The efficacy of COVID‐19 convalescent plasma (CCP) as a treatment for hospitalized patients with COVID‐19 remains somewhat controversial; however, many studies have not evaluated CCP documented to have high neutralizing antibody titer by a highly accurate assay. To evaluate the correlation of the administration of CCP with titer determined by a live viral neutralization assay with 7‐ and 28‐day death rates during hospitalization, a total of 23 118 patients receiving a single unit of CCP were stratified into two groups: those receiving high titer CCP (>250 50% inhibitory dilution, ID50; n = 13 636) or low titer CCP (≤250 ID50; n = 9482). Multivariable Cox regression was performed to assess risk factors. Non‐intubated patients who were transfused with high titer CCP showed 1.1% and 1.7% absolute reductions in overall 7‐ and 28‐day death rates, respectively, compared to those non‐intubated patients receiving low titer CCP. No benefit of CCP was observed in intubated patients. The relative benefit of high titer CCP was confirmed in multivariable Cox regression. Administration of CCP with high titer antibody content determined by live viral neutralization assay to non‐intubated patients is associated with modest clinical efficacy. Although shown to be only of modest clinical benefit, CCP may play a role in the future should viral variants develop that are not neutralized by other available therapeutics.

Clinical manifestations of Coronavirus Disease 2019 (COVID- 19) , caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, range from mild and self-limited to life-threatening respiratory, systemic illness, and death. 1 Potential therapeutics have been proposed or investigated, including antivirals, corticosteroids, immune therapies, antibiotics, and anticoagulation. 2 One of the earliest proposed therapies was CP collected from recovered patients for use as a passive immune therapy, 3, 4 whereby antibodies can be transferred from recovered patients to others to protect from illness or treat active disease. Historically, such approaches appear most effective in the earliest phases of illness, or as prophylaxis. 5 Although CP is frequently one of the earliest available therapies following the spread of a newly emergent infectious disease, its efficacy has only rarely been examined in randomized controlled trials (RCTs). 6, 7 While trials in some viral illnesses, such as Argentine Hemorrhagic Fever, reported positive results, 8 others, including some trials in severe type A influenza, have not. 9 Historical data has suggested possible benefit in the case of other respiratory virus infections, including coronaviruses such as SARS-CoV-1 and Middle Eastern Respiratory Syndrome, but the interpretation of such studies is limited by their non-randomized designs. 10, 11 Factors complicating the rigorous study of CP include the following: the urgent nature of the outbreaks in which CP use is usually considered (which can limit the ability to mobilize resources for clinical trials); the heterogeneous nature of the product; its decentralized manufacture; limitations in the ability to quantify the biologic activity; and eventual availability of alternative therapies, such as antivirals, purified preparations of immune globulins, or monoclonal antibodies, that may not carry some of the risks and practical challenges associated with transfusion of blood products such as plasma.

During the COVID-19 pandemic, initial preclinical animal models suggested potential benefit with passive immune therapies, [12] [13] [14] and non-human primate models found passive transfer of immunoglobulins could protect against infection, and provide therapeutic efficacy following viral challenge, in a dose-dependent manner. 15, 16 Additionally, early in the pandemic, case series reported positive outcomes in patients treated with CP from donors recovered from COVID-19 (COVID-19 Convalescent Plasma, CCP). [17] [18] [19] Considering the available data, the limited treatment options, and the historical precedent, FDA made CCP available for use starting in April 2020. This was initially under individual patient emergency Investigational New Drug applications (eINDs) and subsequently also under a national expanded access protocol (EAP) sponsored by the Mayo Clinic that ultimately transfused more than 90 000 patients by August 2020 when enrollment was closed. A key aspect of the EAP was providing access to CCP at community hospitals. Concurrently, several RCTs moved forward under IND, including various trial designs and study populations, such as prophylaxis, early outpatient use, and hospitalized patients with severe disease. 20, 21 Initial reports from the Mayo-sponsored EAP demonstrated an acceptable safety profile; adverse event rates were consistent with transfusion of non-immune plasma. 22 Several observational or non-randomized studies found positive outcomes compared to matched controls. [23] [24] [25] [26] However, early RCT data were largely limited to two trials that were stopped early. 27, 28 These trials failed to demonstrate benefit in their primary endpoints at the time of stopping and were underpowered to detect clinically meaningful benefit. Considering limitations in available data as of August 2020, as the scale of the pandemic and CCP use under the EAP continued to grow, preliminary data on the potential efficacy of CCP were needed to guide regulatory decision making.

This situation provided the impetus to use real world evidence (RWE) generated from the large number of individuals enrolled in the EAP to assess the efficacy of CCP using SARS-CoV-2 antibody titers determined by a highly accurate live viral neutralization assay. Quantitative serologic and neutralizing antibody tests of CCP donations were unavailable at the time the EAP was established and would remain limited until late 2020. 29 Therefore, for EAP transfusions, both serologic and neutralizing antibody titers were unknown at the time of CCP infusion. The random nature of the CCP titers administered was used to assess the clinical efficacy of CCP by comparing outcomes in low versus high titer and early versus late CCP infusions. We hypothesized that a dose-response relationship between live viral neutralizing antibody titers and clinical outcomes could provide insight into potential efficacy of CCP.

The EAP was a national study of hospitalized adults with COVID-19 sponsored by the Mayo Clinic (NCT04338360). Written informed consent was obtained in accordance with applicable regulations and with oversight from the sponsor's Institutional Review Board. The patients and institutions participating in the EAP for CCP have been previously described. 22 Greater than 99.9% of transfusions were performed between April 4th to August 31st, 2020. Patients were categorized by HHS regions based on the transfusing hospital location. The analysis was limited to patients who had a known intubation status at time of transfusion (43 "unknown" cases excluded) and who had received only one unit of CCP with a reported live viral neutralization titer, to reduce confounding due to multiple exposures at various doses from different donors. Subjects enrolled in the EAP were followed during their hospital stay and not after discharge. Considering this limitation, the primary analyses assumed survival after discharge. As a more conservative approach, the 7-and 28-day death rates for patients remaining in the hospital (for whom survival could be directly observed) were also assessed. This approach required that a patient had accumulated at least 7 or 28 days of follow-up time or have a recorded death to calculate the 7-and 28-day death rates, respectively. Due to this follow-up time constraint to assess survival, 7-day death rate denominators were larger than 28-day death rate denominators, as patients would be discharged in the intervening time period. A detailed description of patient characteristics and attrition observed from the 7-and 28-day analyses is included in Table 1 . 30 

Institute on a high throughput platform (BROAD PRNT). Vero E6-TMPRSS2 were seeded at 10000 cells per well the day prior to infection in a CellCarrier-384 ultra-microplate (Perkin Elmer). Patient plasma samples were tested at a starting dilution of 1:40 and were serially diluted 2-fold up to 1:5120. Serially diluted patient plasma was mixed separately with diluted SARS-CoV-2 live virus (D614) and incubated at 37°C with 5% CO2 for 1 hour; after which the plasma-virus complexes were added to the Vero E6-TMPRSS2 cells and incubated at 37°C with 5% CO2 for 48 hours. Cells were then fixed using 4% paraformaldehyde in PBS for 2 hours at room temperature, washed, and incubated with diluted anti-SARS-CoV/SARS-CoV-2 nucleoprotein mouse antibody (Sino Biological) for 1.5 hours at room temperature. They were subsequently incubated 

Due to the lack of a control cohort in this observational study, the analysis relied on CCP of varying antibody titers being randomly distributed to patients because the titer of the administered CCP was not known a priori. Patients were assigned into 2 prespecified treatment groups, depending on whether they received "high" (≥250) or All analyses were conducted in R (v3.6, https://www.R-project.

org/), using base packages, and the "survminer" package for constructing survival plots.

The baseline patient characteristics are provided in In the overall population, when comparing patients transfused with high versus low titer CCP in the overall population, there was a modest but statistically significant 1.0% (95% CI = 0.24, 1.78) absolute reduction in 7-day mortality ( Figure 1A , Table 2 ), and a 1.5%

(95% CI = 0.43, 2.67) absolute reduction in 28-day mortality T A B L E 2 7-and 28-day death rates grouped by broad ID 50 titers and intubation status numbers in the "All patient" rows for 7-day and 28-day death rates correspond to the horizontal bar graphs displayed in Figure 1 , which assumes survival after discharge F I G U R E 1 7-and 28-day Death Rates Grouped by Broad ID50 Titers and Intubation Status -Panel A and B report 7-and 28-day death rates, for all patients (assuming survival after discharge), intubated patients, and non-intubated patients (colored green, blue, and orange, respectfully). Patient death rates were grouped based on prospectively defined titer categories of "high" and "low," defined as ≥250 and <250 units based on the neutralization titer. The statistical significance in death rates between the titer categories of all CCP transfused patients (green), intubated patients (blue), and non-intubated patients (orange) was assessed using the Chi-squared statistic without correction. Panel C reports Kaplan-Meier estimates grouped by high and low Broad ID50 titers. The survival probabilities for all patients (assuming survival after discharge) were plotted for the high (≥250, colored blue) and low (<250, colored orange) titer CCP with 95% confidence intervals shown in a lighter hue. The log-rank statistic was used as a statistical test to determine differences between the two patient subgroups. The number of patients at risk for the high and low titer subgroups are provided below the plot ( Figure 1B , Table 2 ). The reduced mortality for patients receiving high versus low titer CCP was also observed when restricting analysis to patients who remained hospitalized over the assessed time frame (i.e., excluding those who were discharged during the observation period Note: Results were analyzed by overall survival (hazard ratio for death) within the subgroups. p-values that are italicized indicate a significant difference compared to the reference category, which are denoted by a hazard ratio of "1". 1.15) . Patients also showed a trend in increasing hazard for days from diagnosis to transfusion, albeit non-significant. To further explore the temporal nature of survival, logistic regression was performed, which revealed that the months after April showed a statistically significant reduction in mortality (Table S2) , while the proportions of high versus low titer CCP transfused were similar across the study period (Table S3 ).

Our study was able to leverage the expected random distribu- titer CCP in earlier and less severe disease, [46] [47] [48] [49] [50] [51] [52] [53] or when used in those with impaired immunity. [55] [56] [57] Interpretation of RCT data, including those in recent metaanalyses, 58,59 is made challenging for multiple reasons: 1) the use of either untitered plasma or plasma qualified by serologic testing alone,

2) high heterogeneity in study populations and dosing strategies, and

3) the treatment of subjects at a median of 8 days or later where it is now apparent that humoral immune responses are well-developed in a large proportion of patients. 60 Theoretically, optimal patient and product selection for passive immune therapy (e.g., use of high neutralization titer CCP early in the immune response or early viremic stage, or use in patients with sub-optimal immune responses) has proven difficult to achieve in large RCTs of CCP reported to date, although subgroup analyses may ultimately be informative. [61] [62] [63] [64] An approach to predict the potential benefit of CCP based on patient characteristics was also recently described, and may assist in identifying individuals who will most benefit from CCP transfusion. 65 While live viral assays are the gold standard for neutralizing antibody The multivariable regression analyses also confirmed that survival benefit was associated with transfusion of high titer over low titer CCP.

Conversely, poorer survival was associated with increasing age, male gender, intubation at time of enrollment, and Black or African American race, which are consistent with prior clinical experience. [67] [68] [69] The increased mortality associated with Black or African American race highlights the continued importance of monitoring and addressing health disparities in racial and ethnic minorities. The reduced hazard observed for HHS regions 7 and 8 may be the result of time-varying regional differences in the epidemiology of COVID-19 related hospitalizations. 70 The challenges of running an optimal RCT of CCP during a pandemic continue to complicate conclusions about efficacy of CCP.

Small trial designs are likely to be underpowered to detect the modest but clinically meaningful benefits demonstrated in this study, and studies of CCP can be limited by designs that often have not considered strain specific neutralization activity, patient weight, and dose and timing of transfusion relative to the initial infection, symptom onset, or the humoral immune response (i.e., recipient serostatus). In any given patient, duration of symptoms is likely to be an imprecise surrogate for the stage of the immune response. Results of studies in the hospitalized population, in which effects may be present only in subgroups, thus need to be considered in the context of the timing of CCP transfusion relative to onset of illness, host immune status, and the neutralizing activity of CCP transfused. Investigation of how to best use CCP, and which patients may most benefit, is ongoing; RCTs, and assessment of subgroups within RCTs, will continue to be vital to determine the potential role of CCP in management of COVID-19.

Despite the limitations, we were able to use RWE to demonstrate an association between high-titer CCP and better outcomes for patients. 

Mild or moderate Covid-19

COVID-19) Treatment Guidelines. National Institutes of Health

The convalescent sera option for containing COVID-19

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Passive antibody therapy for infectious diseases

Convalescent plasma: therapeutic Hope or hopeless strategy in the SARS-CoV-2 pandemic

COVID-19 convalescent plasma: now is the time for better science

Efficacy of immune plasma in treatment of argentine haemorrhagic fever and association between treatment and a late neurological syndrome

Anti-influenza immune plasma for the treatment of patients with severe influenza a: a randomised, double-blind, phase 3 trial

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Correlates of protection against SARS-CoV-2 in rhesus macaques

Use of convalescent serum reduces severity of COVID-19 in nonhuman primates

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection

International survey of trials of convalescent plasma to treat COVID-19 infection

A scoping review of registered clinical trials of convalescent plasma for COVID-19 and a framework for accelerated synthesis of trial evidence (FAST evidence)

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19: a randomized clinical trial

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients

Convalescent plasma antibody levels and the risk of death from Covid-19

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial)

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Convalescent plasma in critically ill patients with Covid-19

Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial

Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19

DAWn-plasma investigators. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19

Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York: a double-blind randomized trial

Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19

Early convalescent plasma therapy and mortality among US veterans hospitalized with nonsevere COVID-19: an observational analysis emulating a target trial

Association of Convalescent Plasma Treatment with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19 in the community setting

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

A matched cohort study of convalescent plasma therapy for COVID-19

Convalescent plasma for preventing critical illness in COVID-19: a phase 2 trial and immune profile

Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study

Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing hightiter anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG

Early mortality benefit with COVID-19 convalescent plasma: a matched control study

Use of convalescent plasma in COVID-19 patients with immunosuppression

Association of Convalescent Plasma Therapy with Survival in patients with hematologic cancers and COVID-19

Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Association of Convalescent Plasma Treatment with Clinical Outcomes in patients with COVID-19: a systematic review and meta-analysis

Adaptive immunity to SARS-CoV-2 and COVID-19

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label

Early high-titer plasma therapy to prevent severe Covid-19 in older adults

Early convalescent plasma for high-risk outpatients with Covid-19

Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may Bbnefit from convalescent plasma

Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays

Assessment of serological assays for identifying high titer convalescent plasma

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers

Risk factors associated with in-hospital mortality in a US National Sample of patients with COVID-19

Variation in US Hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic

We thank Dr. Dean Follmann at the National Institutes of Health for his contributions to the study.

The authors declare no conflicts of interest.

Research data are not shared.

https://orcid.org/0000-0001-5619-4404